Cargando…
Receptor Specificity Engineering of TNF Superfamily Ligands
The tumor necrosis factor (TNF) ligand family has nine ligands that show promiscuity in binding multiple receptors. As different receptors transduce into diverse pathways, the study on the functional role of natural ligands is very complex. In this review, we discuss the TNF ligands engineering for...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781899/ https://www.ncbi.nlm.nih.gov/pubmed/35057080 http://dx.doi.org/10.3390/pharmaceutics14010181 |
_version_ | 1784638191165243392 |
---|---|
author | Suo, Fengzhi Zhou, Xinyu Setroikromo, Rita Quax, Wim J. |
author_facet | Suo, Fengzhi Zhou, Xinyu Setroikromo, Rita Quax, Wim J. |
author_sort | Suo, Fengzhi |
collection | PubMed |
description | The tumor necrosis factor (TNF) ligand family has nine ligands that show promiscuity in binding multiple receptors. As different receptors transduce into diverse pathways, the study on the functional role of natural ligands is very complex. In this review, we discuss the TNF ligands engineering for receptor specificity and summarize the performance of the ligand variants in vivo and in vitro. Those variants have an increased binding affinity to specific receptors to enhance the cell signal conduction and have reduced side effects due to a lowered binding to untargeted receptors. Refining receptor specificity is a promising research strategy for improving the application of multi-receptor ligands. Further, the settled variants also provide experimental guidance for engineering receptor specificity on other proteins with multiple receptors. |
format | Online Article Text |
id | pubmed-8781899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87818992022-01-22 Receptor Specificity Engineering of TNF Superfamily Ligands Suo, Fengzhi Zhou, Xinyu Setroikromo, Rita Quax, Wim J. Pharmaceutics Review The tumor necrosis factor (TNF) ligand family has nine ligands that show promiscuity in binding multiple receptors. As different receptors transduce into diverse pathways, the study on the functional role of natural ligands is very complex. In this review, we discuss the TNF ligands engineering for receptor specificity and summarize the performance of the ligand variants in vivo and in vitro. Those variants have an increased binding affinity to specific receptors to enhance the cell signal conduction and have reduced side effects due to a lowered binding to untargeted receptors. Refining receptor specificity is a promising research strategy for improving the application of multi-receptor ligands. Further, the settled variants also provide experimental guidance for engineering receptor specificity on other proteins with multiple receptors. MDPI 2022-01-13 /pmc/articles/PMC8781899/ /pubmed/35057080 http://dx.doi.org/10.3390/pharmaceutics14010181 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Suo, Fengzhi Zhou, Xinyu Setroikromo, Rita Quax, Wim J. Receptor Specificity Engineering of TNF Superfamily Ligands |
title | Receptor Specificity Engineering of TNF Superfamily Ligands |
title_full | Receptor Specificity Engineering of TNF Superfamily Ligands |
title_fullStr | Receptor Specificity Engineering of TNF Superfamily Ligands |
title_full_unstemmed | Receptor Specificity Engineering of TNF Superfamily Ligands |
title_short | Receptor Specificity Engineering of TNF Superfamily Ligands |
title_sort | receptor specificity engineering of tnf superfamily ligands |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781899/ https://www.ncbi.nlm.nih.gov/pubmed/35057080 http://dx.doi.org/10.3390/pharmaceutics14010181 |
work_keys_str_mv | AT suofengzhi receptorspecificityengineeringoftnfsuperfamilyligands AT zhouxinyu receptorspecificityengineeringoftnfsuperfamilyligands AT setroikromorita receptorspecificityengineeringoftnfsuperfamilyligands AT quaxwimj receptorspecificityengineeringoftnfsuperfamilyligands |